```
FILE 'REGISTRY' ENTERED AT 14:11:03 ON 01 JUN 2009
COPYRIGHT (C) 2009 American Chemical Society (ACS)

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   0.48      18.73

=> file reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   0.48      18.73

FILE 'REGISTRY' ENTERED AT 14:11:16 ON 01 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   31 MAY 2009  HIGHEST RN 1151391-70-6
DICTIONARY FILE UPDATES:  31 MAY 2009  HIGHEST RN 1151391-70-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10590623_new_3.str
```





chain nodes :
7 8 9 31
ring nodes :
1 2 3 4 5 12 13 14 15 16 17 18 19 20 22 23 24 25 26 27 28 29
30
chain bonds :
2-7 3-8 5-9 7-31
ring bonds :
1-2 1-5 2-3 3-4 4-5 12-13 12-17 13-14 14-15 15-16 16-17 16-18 17-20
18-19 19-20 22-23 22-27 23-24 24-25 25-26 26-27 26-28 27-30 28-29 29-30
exact/norm bonds :
1-2 1-5 2-3 2-7 3-4 3-8 4-5 5-9 7-31 16-18 17-20 18-19 19-20 26-28
27-30 28-29 29-30
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17 22-23 22-27 23-24 24-25 25-26 26-27

G1:O,S

G2:C,O,S,N

G3:O,S,N

G4:C,N

G5:[*1],[*2]

```
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  7:CLASS  8:CLASS  9:CLASS  12:CLASS  13:Atom
14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom  20:Atom  22:Atom  23:Atom
24:Atom  25:Atom
26:Atom  27:Atom  28:Atom  29:Atom  30:Atom  31:CLASS



L5      STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l5 sam
SAMPLE SEARCH INITIATED 14:11:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       12 TO ITERATE

100.0% PROCESSED       12 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           33 TO      447
PROJECTED ANSWERS:               4 TO      200

L6            4 SEA SSS SAM L5

=> s l5 full
FULL SEARCH INITIATED 14:11:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      278 TO ITERATE

100.0% PROCESSED      278 ITERATIONS                               33 ANSWERS
SEARCH TIME: 00.00.01

L7           33 SEA SSS FUL L5

=>
Uploading C:\Program Files\STNEXP\Queries\10590623_new_4.str
```






chain nodes :
7 8 9 31
ring nodes :
1 2 3 4 5 12 13 14 15 16 17 18 19 20 22 23 24 25 26 27 28 29
30
chain bonds :
2-7 3-8 5-9 7-31
ring bonds :
1-2 1-5 2-3 3-4 4-5 12-13 12-17 13-14 14-15 15-16 16-17 16-18 17-20
18-19 19-20 22-23 22-27 23-24 24-25 25-26 26-27 26-28 27-30 28-29 29-30
exact/norm bonds :
1-2 1-5 2-3 2-7 3-4 3-8 4-5 5-9 7-31 16-18 17-20 18-19 19-20 26-28
27-30 28-29 29-30
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17 22-23 22-27 23-24 24-25 25-26 26-27

G1:O,S

G2:C,O,S,N

G3:O,S,N

G4:C,N

G5:[*1],[*2]

```
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  7:CLASS  8:CLASS  9:CLASS  12:CLASS  13:Atom
14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom  20:Atom  22:Atom  23:Atom
24:Atom  25:Atom
26:Atom  27:Atom  28:Atom  29:Atom  30:Atom  31:CLASS



L8      STRUCTURE UPLOADED

=> d
L8 HAS NO ANSWERS
L8              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l8 sam
SAMPLE SEARCH INITIATED 14:13:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       12 TO ITERATE

100.0% PROCESSED       12 ITERATIONS                                5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           33 TO      447
PROJECTED ANSWERS:               5 TO      234

L9            5 SEA SSS SAM L8

=> s l8 full
FULL SEARCH INITIATED 14:14:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      278 TO ITERATE

100.0% PROCESSED      278 ITERATIONS                             137 ANSWERS
SEARCH TIME: 00.00.01

L10         137 SEA SSS FUL L8

=> file marpat
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   373.20     391.93

FILE 'MARPAT' ENTERED AT 14:14:14 ON 01 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 150 ISS 22 (20090529/ED)

MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US  20090099165 16 APR 2009
```

```
DE 102007048335 16 APR 2009
EP      2048146 15 APR 2009
JP   2009081431 16 APR 2009
WO   2009051956 23 APR 2009
GB      2452157 25 FEB 2009
FR      2921926 10 APR 2009
RU      2352587 20 APR 2009
CA      2605026 28 MAR 2009

The new MARPAT User Guide is now available at:
 http://www.cas.org/support/stngen/stndoc/marpat.html.

=> s l10 sam
SAMPLE SEARCH INITIATED 14:14:18 FILE 'MARPAT'
SAMPLE SCREEN SEARCH COMPLETED -      597 TO ITERATE

100.0% PROCESSED      597 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       10497 TO    13383
PROJECTED ANSWERS:              1 TO       80

L11           1 SEA SSS SAM L8

=> s l10 full
FULL SEARCH INITIATED 14:14:22 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -    12140 TO ITERATE

100.0% PROCESSED    12140 ITERATIONS                                6 ANSWERS
SEARCH TIME: 00.00.04

L12           6 SEA SSS FUL L8

=> d l12 ibib ab 1-6

L12  ANSWER 1 OF 6  MARPAT  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         147:365484  MARPAT <<LOGINID::20090601>>
TITLE:                    Preparation of thiazolones for use as PI3 kinase
                          inhibitors
INVENTOR(S):              Dhanak, Dashyant; Knight, Steven David
PATENT ASSIGNEE(S):       Smithkline Beecham Corporation, USA
SOURCE:                   PCT Int. Appl., 129 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2007103755      A2   20070913       WO 2007-US63113  20070302
     WO 2007103755      A3   20080306
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
             KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN,
             MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
             RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
```

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1993536 A2 20081126 EP 2007-757756 20070302

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, HR

US 20090048252 A1 20090219 US 2008-281181 20080829

PRIORITY APPLN. INFO.: US 2006-778272P 20060302

WO 2007-US63113 20070302

AB The title compds. I [R = H, (un)substituted aryl, cycloalkyl, alkyl; R10 = H, alkyl, (CH2)mOH, (CH2)mCO2H; m = 0-6; Y = O, S, NR11; R11 = H, alkyl, (CH2)pOH, (CH2)pCO2H; p = 0-6; Q = (un)substituted benzoxazolyl, benzimidazolyl, etc.], useful for inhibiting the activity/function of PI3 kinases, were prepared and formulated. E.g., a multi-step synthesis of (5Z)-2-[(2-chlorophenyl)amino]-5-[(1-methyl-1H-benzimidazol-6-yl)methylidene]-1,3-thiazol-4(5H)-one, starting from 3-methoxy-4-nitrobenzoic acid, was given. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones I.

L12 ANSWER 2 OF 6 MARPAT COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 144:398358 MARPAT <<LOGINID::20090601>>

TITLE: PI3 kinase gamma inhibitors for the treatment of anaemia

INVENTOR(S): Wetzker, Reinhard; Mueller, Angelika; Rommel, Christian

PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth. Antilles

SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006040318	A2	20060420	WO 2005-EP55156	20051011
WO 2006040318	A3	20060810		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2005293556	A1	20060420	AU 2005-293556	20051011
CA 2580480	A1	20060420	CA 2005-2580480	20051011
EP 1807075	A2	20070718	EP 2005-801722	20051011

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

CN 101056633	A	20071017	CN 2005-80038804	20051011	
JP 2008515955	T	20080515	JP 2007-536166	20051011	
ZA 2007002435	A	20080625	ZA 2007-2435	20051011	
BR 2005017416	A	20081007	BR 2005-17416	20051011	
IN 2007DN02450	A	20070803	IN 2007-DN2450	20070402	
MX 2007004302	A	20070607	MX 2007-4302	20070411	
NO 2007002393	A	20070509	NO 2007-2393	20070509	
US 20090042773	A1	20090212	US 2007-664969	20070710	
PRIORITY APPLN. INFO.:			EP 2004-104997	20041012	
			WO 2005-EP55156	20051011	

AB This present invention is related to the use of selective PD kinase gamma inhibitors for the manufacture of a medicament for the treatment of disorders related to erythrocyte deficiency. Specifically, the present invention is related to the use of selective PI3 Kinase gamma inhibitors, e.g. substituted azolidinone-vinyl fused-benzene derivs. for the treatment of an anemia, including haemolytic anemia, aplastic anemia and pure red cell anemia. (I) wherein A, X, Y1, Y2, Z, n, R1 and R2 are described in details in the description hereinafter.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 6 MARPAT COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 143:286417 MARPAT <<LOGINID::20090601>>

TITLE: Preparation of thiazolone compounds for inhibiting hYAK3 proteins

INVENTOR(S): Duffy, Kevin J.; Fitch, Duke M.; Goodman, Steven Neal; Hasegawa, Masaichi; Johnson, Neil W.; Kasparec, Jiri; Shaw, Antony N.

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082901	A1	20050909	WO 2005-US6022	20050224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1718642	A1	20061108	EP 2005-723757	20050224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
JP 2007523957	T	20070823	JP 2007-500992	20050224
US 20070249599	A1	20071025	US 2006-590623	20060824
PRIORITY APPLN. INFO.:			US 2004-547543P	20040225
			WO 2005-US6022	20050224

OTHER SOURCE(S): CASREACT 143:286417

AB Title compds. I [wherein R = H, (un)substituted aryl or (cyclo)alkyl; Y =

O, S or NR11; R10, R11 = H, alkyl, (CH2)mOH, (CH2)mCOOH; m = 0-6; Q = (un)substituted benzimidazol-6-yl, benzotriazol-6-yl or benzoxazol-6-yl, or pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof] were prepared for inhibiting hYAK3 proteins. For instance, cyclization of Me 4-amino-3-hydroxybenzoate with tri-Et orthoacetate to II (X = COOMe) (72% yield) followed by reduction with LiAlH4 led to alc. II (X = CH2OH) (58% yield). This compound underwent oxidation with PCC to afford aldehyde II (X = CHO) (66% yield), which was condensed with thiazolidinone III in the presence of piperidine to give IV (15% yield). Compds. IV showed inhibition against hYAK3 kinase enzyme with pIC50 in the range of 8.99-8. Therefore, I and their pharmaceutical compns. (examples given) are useful for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins, especially diseases of the erythroid and hematopoietic systems.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 6 MARPAT COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 141:94293 MARPAT <<LOGINID::20090601>>

TITLE: Preparation and formulation of thrombopoietin mimetics

INVENTOR(S): Heerding, Dirk A.; Price, Alan T.; Safonov, Igor

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054515	A2	20040701	WO 2003-US39633	20031212
WO 2004054515	A3	20041118		
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003297925	A1	20040709	AU 2003-297925	20031212
EP 1581527	A2	20051005	EP 2003-796996	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514951	T	20060518	JP 2004-560836	20031212
US 20060084682	A1	20060420	US 2005-538252	20050609
PRIORITY APPLN. INFO.:			US 2002-433482P	20021213
			WO 2003-US39633	20031212

AB Invented are non-peptide thrombopoietin (TPO) mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected benzimidazole derivative For example, a TPO receptor agonist, (E)-3-[2-[6-(4-tert-butylphenyl)pyridin-2-yl]-1H-benzimidazol-5-yl]-2-methylacrylic acid (I), was prepared and formulated into tablets containing I 20 mg, calcium sulfate dihydrate 30 mg, sucrose 4 mg, starch 2 mg, talc 1 mg, and stearic acid 0.5 mg.

L12 ANSWER 5 OF 6 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 140:128412 MARPAT <<LOGINID::20090601>>
TITLE: Preparation of azolidinone-vinyl fused-benzene derivatives for therapeutic uses as PI3 kinase inhibitors
INVENTOR(S): Rueckle, Thomas; Jiang, Xuliang; Gaillard, Pascale; Church, Dennis; Vallotton, Tania
PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth. Antilles
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007491	A1	20040122	WO 2003-EP50302	20030710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040092561	A1	20040513	US 2002-289998	20021107
CA 2493843	A1	20040122	CA 2003-2493843	20030710
AU 2003255528	A1	20040202	AU 2003-255528	20030710
BR 2003012752	A	20050426	BR 2003-12752	20030710
BR 2003012650	A	20050503	BR 2003-12650	20030710
EP 1549644	A1	20050706	EP 2003-763907	20030710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1681811	A	20051012	CN 2003-821416	20030710
JP 2005538188	T	20051215	JP 2005-505076	20030710
ZA 2005000162	A	20060726	ZA 2005-162	20050107
MX 2005000453	A	20050323	MX 2005-453	20050110
NO 2005000654	A	20050315	NO 2005-654	20050208
US 20060122176	A1	20060608	US 2005-520621	20050824

PRIORITY APPLN. INFO.: EP 2002-100798 20020710
US 2002-289998 20021107
WO 2003-EP50302 20030710

AB The present invention is related to the preparation of azolidinedione-vinyl fused-benzene derivs., such as I [R1 = H, CN, carboxy, acyl, alkoxy, halogen, acyloxy, etc.; A = fused heterocyclic or carbocyclic ring; Y1, Y2 = S, O, NH], and their use in pharmaceutical comps. as PI3 kinase (PI3K) inhibitors. These azolidinones are claimed for use in the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, cancer, graft rejection, lung injuries, chronic obstructive pulmonary disease, anaphylactic shock, fibrosis, psoriasis, allergic diseases, asthma, stroke or ischemic conditions, ischemia-reperfusion, platelet aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, angiogenesis, invasion metastasis in melanoma and Kaposi's sarcoma, sepsis, transplantation, pancreatitis, multi-organ failure, glomerulosclerosis, glomerulonephritis, progressive renal fibrosis, endothelial and epithelial

injuries in the lung or in general lung airways inflammation. Further, these azolidinones are claimed for use in the treatment of atherosclerosis, hypertrophy, cardiac myocyte dysfunction, elevated blood pressure, vasoconstriction, Alzheimer's disease, Huntington's disease, CNS trauma, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, thrombosis, and brain infection/inflammation such as meningitis or encephalitis. Thus, azolidinone II was prepared via a condensation reaction of piperonal with 2,4-thiazolidinedione using β-alanine in acetic acid and stirring at 100° for 3 h. Some of the prepared azolidinones were assayed for PI3Kγ inhibition using a high throughput PI3K lipid kinase binding assay. Tablet, capsule, liquid and injectable pharmaceutical compns. were presented.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 6 MARPAT COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 140:128411 MARPAT <<LOGINID::20090601>>

TITLE: Preparation of dioxothiazolylidenemethyl derivatives for increasing spermatozoa motility

INVENTOR(S): De Luca, Giampiero

PATENT ASSIGNEE(S): Applied Research Systems Ars Holding NV, Neth. Antilles

SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006916	A1	20040122	WO 2003-EP50303	20030710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489779	A1	20040122	CA 2003-2489779	20030710
AU 2003255529	A1	20040202	AU 2003-255529	20030710
AU 2003255529	B2	20081120		
EP 1531813	A1	20050525	EP 2003-763908	20030710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006500327	T	20060105	JP 2004-520680	20030710
NO 2005000713	A	20050210	NO 2005-713	20050210
US 20050222225	A1	20051006	US 2005-519685	20050504
PRIORITY APPLN. INFO.:			EP 2002-100799	20020710
			EP 2002-102876	20021223
			WO 2003-EP50303	20030710

AB Title compds. I [X = S, O, NH; Y1-2 = S, O, NH; Cy = 5-8 membered, optionally fused, carbo/heterocyclic ring] are prepared For instance, thiazolidine-2,4-dione is condensed with piperonal (HOAc, β-alanine, 3 h, 100°) to give II. Selected examples have IC50 < 1 μM for the phosphatidylinositol-3-kinase (PI3Kγ) receptor. I are useful for the improvement of spermatozoa fertilization activity; in particular

for the increase of spermatozoa motility. Furthermore, I are used to treat infertility and assisted reproduction techniques (ART).
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caplus
COST IN U.S. DOLLARS — SINCE FILE ENTRY: 87.39 — TOTAL SESSION: 479.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) — SINCE FILE ENTRY: -4.68 — TOTAL SESSION: -4.68
CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 14:17:46 ON 01 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Jun 2009 VOL 150 ISS 23
FILE LAST UPDATED: 31 May 2009 (20090531/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate

=> d his

(FILE 'HOME' ENTERED AT 13:58:33 ON 01 JUN 2009)

FILE 'CAPLUS' ENTERED AT 13:59:14 ON 01 JUN 2009

FILE 'CAPLUS' ENTERED AT 14:00:03 ON 01 JUN 2009
E US20070249599
E US20070249599A1
E 2007:1022578/AN
L1 1 S 2007:1022578/AN
L2 1 S 2005:979651/AN
SEL RN

FILE 'REGISTRY' ENTERED AT 14:04:52 ON 01 JUN 2009
L3 282 S E1-E282

```
     FILE 'CAPLUS' ENTERED AT 14:05:55 ON 01 JUN 2009
L4         16600 S L3 AND PAC/RL

     FILE 'REGISTRY' ENTERED AT 14:08:02 ON 01 JUN 2009

     FILE 'REGISTRY' ENTERED AT 14:11:16 ON 01 JUN 2009
L5               STRUCTURE UPLOADED
L6             4 S L5 SAM
L7            33 S L5 FULL
L8               STRUCTURE UPLOADED
L9             5 S L8 SAM
L10          137 S L8 FULL

     FILE 'MARPAT' ENTERED AT 14:14:14 ON 01 JUN 2009
L11            1 S L10 SAM
L12            6 S L10 FULL

     FILE 'CAPLUS' ENTERED AT 14:17:46 ON 01 JUN 2009

=> s l7
L13            4 L7

=> d l13 ibib gi abs hitstr 1-4

L13  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2007:1022578  CAPLUS <<LOGINID::20090601>>
DOCUMENT NUMBER:          147:365484
TITLE:                    Preparation of thiazolones for use as PI3 kinase
                          inhibitors
INVENTOR(S):              Dhanak, Dashyant; Knight, Steven David
PATENT ASSIGNEE(S):       Smithkline Beecham Corporation, USA
SOURCE:                   PCT Int. Appl., 129 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     WO 2007103755        A2    20070913    WO 2007-US63113        20070302
     WO 2007103755        A3    20080306
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
             KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN,
             MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
             RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
     EP 1993536           A2    20081126    EP 2007-757756         20070302
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, HR
     US 20090048252       A1    20090219    US 2008-281181         20080829
PRIORITY APPLN. INFO.:                     US 2006-778272P     P  20060302
                                           WO 2007-US63113     W  20070302
```

OTHER SOURCE(S): MARPAT 147:365484

GI



I

GI



I

AB The title compds. I [R = H, (un)substituted aryl, cycloalkyl, alkyl; R10 = H, alkyl, (CH2)mOH, (CH2)mCO2H; m = 0-6; Y = O, S, NR11; R11 = H, alkyl, (CH2)pOH, (CH2)pCO2H; p = 0-6; Q = (un)substituted benzoxazolyl, benzimidazolyl, etc.], useful for inhibiting the activity/function of PI3 kinases, were prepared and formulated. E.g., a multi-step synthesis of (5Z)-2-[(2-chlorophenyl)amino]-5-[(1-methyl-1H-benzimidazol-6-yl)methylidene]-1,3-thiazol-4(5H)-one, starting from 3-methoxy-4-nitrobenzoic acid, was given. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones I.

IT 864274-33-9P 864274-35-1P 949581-81-1P
949581-83-3P 949581-85-5P 949581-86-6P
949581-87-7P 949581-89-9P 949581-91-3P
949581-92-4P 949581-93-5P 949581-96-8P
949581-97-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted thiazolones as PI3 kinase inhibitors useful in combination therapy of diseases)

RN 864274-33-9 CAPLUS

CN Acetamide, N-[6-[[2-[(2-bromophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]-1H-benzimidazol-2-yl]-2-(dimethylamino)- (CA INDEX NAME)



RN 864274-35-1 CAPLUS
CN Carbamic acid, N-[6-[(Z)-(2-[(2-bromophenyl)amino]-4-oxo-5(4H)-thiazolylidene)methyl]-1H-benzimidazol-2-yl]-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 949581-81-1 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[(2-phenyl-1H-benzimidazol-6-yl)methylene]-, (2Z,5Z)-, compd. with piperidine (1:1) (CA INDEX NAME)

CM 1

CRN 949581-80-0
CMF C23 H14 C12 N4 O S



CM 2

CRN 110-89-4
CMF C5 H11 N

RN 949581-83-3 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(1-methylethyl)-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)- (CA INDEX NAME)



RN 949581-85-5 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(2-methylpropyl)-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)-, compd. with piperidine (1:1) (CA INDEX NAME)

CM 1

CRN 949581-84-4
CMF C21 H18 Cl2 N4 O S



CM 2

CRN 110-89-4
CMF C5 H11 N

RN 949581-86-6 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(3-pyridinyl)-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)- (CA INDEX NAME)



RN 949581-87-7 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(hydroxymethyl)-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)- (CA INDEX NAME)



RN 949581-89-9 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(2-hydroxyethyl)-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)- (CA INDEX NAME)



RN 949581-91-3 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(2-pyridinyl)-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)- (CA INDEX NAME)



RN 949581-92-4 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[(2-methyl-1H-benzimidazol-6-yl)methylene]-, (2Z,5Z)- (CA INDEX NAME)



RN 949581-93-5 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(4-pyridinyl)-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)- (CA INDEX NAME)



RN 949581-96-8 CAPLUS
CN 4-Thiazolidinone, 5-[[2-(aminomethyl)-1H-benzimidazol-6-yl]methylene]-2-[(2,6-dichlorophenyl)imino]-, (2Z,5Z)- (CA INDEX NAME)



RN 949581-97-9 CAPLUS
CN 4-Thiazolidinone, 5-(1H-benzimidazol-6-ylmethylene)-2-[(2,6-dichlorophenyl)imino]-, (2Z,5Z)- (CA INDEX NAME)



IT 864274-37-3P 949581-99-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted thiazolones as PI3 kinase inhibitors useful in combination therapy of diseases)
RN 864274-37-3 CAPLUS

CN 4(5H)-Thiazolone, 5-[(2-amino-1H-benzimidazol-6-yl)methylene]-2-[(2-bromophenyl)amino]- (CA INDEX NAME)



RN 949581-99-1 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1H-benzimidazol-6-yl]methylene]-, (2Z,5Z)- (CA INDEX NAME)



L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:1022549 CAPLUS <<LOGINID::20090601>>
DOCUMENT NUMBER: 147:365483
TITLE: Preparation of thiazolones for use as PI3 kinase inhibitors
INVENTOR(S): Dhanak, Dashyant; Knight, Steven David
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007103754	A2	20070913	WO 2007-US63112	20070302
WO 2007103754	A3	20080306		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1993535 A2 20081126 EP 2007-757755 20070302
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, HR
US 20090023742 A1 20090122 US 2008-281179 20080829
PRIORITY APPLN. INFO.: US 2006-778428P P 20060302
WO 2007-US63112 W 20070302
OTHER SOURCE(S): MARPAT 147:365483

GI



GI



AB The title compds. I [R = cycloalkyl, naphthyl, (un)substituted Ph, etc.; Q = benzofuranyl, quinolinyl, Ph, etc.], useful for inhibiting the activity/function of PI3 kinases, were prepared E.g., a multi-step synthesis of II, starting 2-chloro-5-fluoroaniline, was given. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones I.

IT 701293-29-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolone compds. as PI3 kinase inhibitors useful in combination therapy of diseases)

RN 701293-29-0 CAPLUS

CN 2(3H)-Benzoxazolone, 5-[[2-[(2-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]- (CA INDEX NAME)



L13 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:979651 CAPLUS <<LOGINID::20090601>>

DOCUMENT NUMBER: 143:286417

TITLE: Preparation of thiazolone compounds for inhibiting hYAK3 proteins

INVENTOR(S): Duffy, Kevin J.; Fitch, Duke M.; Goodman, Steven Neal; Hasegawa, Masaichi; Johnson, Neil W.; Kasparec, Jiri; Shaw, Antony N.

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082901	A1	20050909	WO 2005-US6022	20050224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1718642	A1	20061108	EP 2005-723757	20050224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
JP 2007523957	T	20070823	JP 2007-500992	20050224
US 20070249599	A1	20071025	US 2006-590623	20060824
PRIORITY APPLN. INFO.:			US 2004-547543P P	20040225
			WO 2005-US6022 W	20050224

OTHER SOURCE(S): CASREACT 143:286417; MARPAT 143:286417

GI



I



II



III



IV

GI



I



II



III



IV

AB Title compds. I [wherein R = H, (un)substituted aryl or (cyclo)alkyl; Y = O, S or NR11; R10, R11 = H, alkyl, (CH2)mOH, (CH2)mCOOH; m = 0-6; Q = (un)substituted benzimidazol-6-yl, benzotriazol-6-yl or benzoxazol-6-yl, or pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof] were prepared for inhibiting hYAK3 proteins. For instance, cyclization of Me 4-amino-3-hydroxybenzoate with tri-Et orthoacetate to II

(X = COOMe) (72% yield) followed by reduction with LiAlH4 led to alc. II (X = CH2OH) (58% yield). This compound underwent oxidation with PCC to afford aldehyde II (X = CHO) (66% yield), which was condensed with thiazolidinone III in the presence of piperidine to give IV (15% yield). Compds. IV showed inhibition against hYAK3 kinase enzyme with pIC50 in the range of 8.99-8. Therefore, I and their pharmaceutical compns. (examples given) are useful for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins, especially diseases of the erythroid and hematopoietic systems.

IT 864274-33-9P 864274-35-1P 864274-52-2P
864274-56-6P 864274-61-3P 864274-65-7P
864274-68-0P 864274-73-7P 864274-77-1P
864274-84-0P 864274-85-1P 864274-93-1P
864274-98-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; preparation of thiazolone compds. for inhibiting hYAK3 proteins)

RN 864274-33-9 CAPLUS
CN Acetamide, N-[6-[[2-[(2-bromophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]-1H-benzimidazol-2-yl]-2-(dimethylamino)- (CA INDEX NAME)



RN 864274-35-1 CAPLUS
CN Carbamic acid, N-[6-[(Z)-(2-[(2-bromophenyl)amino]-4-oxo-5(4H)-thiazolylidene)methyl]-1H-benzimidazol-2-yl]-, methyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 864274-52-2 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[(2-phenyl-1H-benzimidazol-5-yl)methylene]-, (2Z,5Z)-, compd. with piperidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 864274-51-1
CMF C23 H14 Cl2 N4 O S



CM 2

CRN 110-89-4
CMF C5 H11 N

RN 864274-56-6 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(1-methylethyl)-1H-benzimidazol-5-yl]methylene]-, (2Z,5Z)- (9CI) (CA INDEX NAME)



RN 864274-61-3 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(2-methylpropyl)-1H-benzimidazol-5-yl]methylene]-, (2Z,5Z)-, compd. with piperidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 864274-60-2
CMF C21 H18 Cl2 N4 O S



CM 2

CRN 110-89-4
CMF C5 H11 N

RN 864274-65-7 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(3-pyridinyl)-1H-benzimidazol-5-yl]methylene]-, (2Z,5Z)- (9CI) (CA INDEX NAME)



RN 864274-68-0 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(hydroxymethyl)-1H-benzimidazol-5-yl]methylene]-, (2Z,5Z)- (9CI) (CA INDEX NAME)



RN 864274-73-7 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(2-hydroxyethyl)-1H-benzimidazol-5-yl]methylene]-, (2Z,5Z)- (9CI) (CA INDEX NAME)



RN 864274-77-1 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(2-pyridinyl)-1H-benzimidazol-5-yl]methylene]-, (2Z,5Z)- (9CI) (CA INDEX NAME)



RN 864274-84-0 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[(2-methyl-1H-benzimidazol-5-yl)methylene]-, (2Z,5Z)- (9CI) (CA INDEX NAME)



RN 864274-85-1 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-(4-pyridinyl)-1H-benzimidazol-5-yl]methylene]-, (2Z,5Z)- (9CI) (CA INDEX NAME)



RN 864274-93-1 CAPLUS
CN 4-Thiazolidinone, 5-[[2-(aminomethyl)-1H-benzimidazol-5-yl]methylene]-2-[(2,6-dichlorophenyl)imino]-, (2Z,5Z)- (9CI) (CA INDEX NAME)



RN 864274-98-6 CAPLUS
CN 4-Thiazolidinone, 5-(1H-benzimidazol-5-ylmethylene)-2-[(2,6-dichlorophenyl)imino]-, (2Z,5Z)- (9CI) (CA INDEX NAME)



IT 864274-37-3P 864274-72-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolone compds. for inhibiting hYAK3 proteins)
RN 864274-37-3 CAPLUS
CN 4(5H)-Thiazolone, 5-[(2-amino-1H-benzimidazol-6-yl)methylene]-2-[(2-bromophenyl)amino]- (CA INDEX NAME)



RN 864274-72-6 CAPLUS
CN 4-Thiazolidinone, 2-[(2,6-dichlorophenyl)imino]-5-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1H-benzimidazol-5-yl]methylene]-, (2Z,5Z)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:467698 CAPLUS <<LOGINID::20090601>>
DOCUMENT NUMBER: 141:38601
TITLE: Preparation of thiazolidinones for inhibiting hYAK3
INVENTOR(S): Hasegawa, Masaichi; Tang, Jun; Sato, Hideyuki
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004047760	A2	20040610	WO 2003-US37658	20031118
WO 2004047760	A3	20041021		
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2507256	A1	20040610	CA 2003-2507256	20031118
AU 2003298693	A1	20040618	AU 2003-298693	20031118
EP 1567112	A2	20050831	EP 2003-796448	20031118
EP 1567112	B1	20081015		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016502	A	20051004	BR 2003-16502	20031118
CN 1742010	A	20060301	CN 2003-80109119	20031118
JP 2006509765	T	20060323	JP 2004-555721	20031118
NZ 539873	A	20080926	NZ 2003-539873	20031118
AT 411302	T	20081015	AT 2003-796448	20031118
ES 2315566	T3	20090401	ES 2003-796448	20031118
IN 2005DN02002	A	20070202	IN 2005-DN2002	20050511
MX 2005005406	A	20050803	MX 2005-5406	20050520
US 20060293338	A1	20061228	US 2006-535690	20060410
PRIORITY APPLN. INFO.:			US 2002-428384P P	20021122
			WO 2003-US37658 W	20031118

OTHER SOURCE(S): MARPAT 141:38601

GI



GI



I



II

AB This invention relates to newly identified compds. I [R = cycloalkyl, naphthyl, (un)substituted Ph, etc.; Q = quinolinyl, dihydrobenzofuranyl, benzodioxanyl, etc.] for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins such as anemia. E.g., a 3-step synthesis of II, starting from 2-chloro-5-fluoroaniline, was given. The compds. I have valuable pharmacol. properties due to their ability to inhibit the hYAK3 kinase as demonstrated by data given for the representative compds. I.

IT 701293-29-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolidinones for inhibiting hYAK3)

RN 701293-29-0 CAPLUS

CN 2(3H)-Benzoxazolone, 5-[[2-[(2-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]- (CA INDEX NAME)




```
=> logoff hold

     (FILE 'HOME' ENTERED AT 13:58:33 ON 01 JUN 2009)

     FILE 'CAPLUS' ENTERED AT 13:59:14 ON 01 JUN 2009

     FILE 'CAPLUS' ENTERED AT 14:00:03 ON 01 JUN 2009
               E  US20070249599
               E US20070249599A1
               E  2007:1022578/AN
L1             1 SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  2007:1022578/AN
               D IBIB
L2             1 SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  2005:979651/AN
               D IBIB
               SEL RN
```

```
                D SCAN

     FILE 'REGISTRY' ENTERED AT 14:04:52 ON 01 JUN 2009
L3           282 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (100-36-7/BI OR
                 100-52-7/BI OR 1003-03-8/BI OR 101869-79-8/BI OR 102191-92-4/BI
                  OR 106-47-8/BI OR 106429-29-2/BI OR 106429-51-0/BI OR
                 106429-52-1/BI OR 108-00-9/BI OR 109-01-3/BI OR 109-85-3/BI OR
                 110-91-8/BI OR 1118-68-9/BI OR 1121-60-4/BI OR 114408-87-6/BI
                 OR 123-00-2/BI OR 13325-10-5/BI OR 136663-23-5/BI OR 136663-40-
                 6/BI OR 141-43-5/BI OR 141-84-4/BI OR 1484-85-1/BI OR 15673-00-
                 4/BI OR 15788-16-6/BI OR 174648-21-6/BI OR 177476-75-4/BI OR
                 17823-27-7/BI OR 181867-19-6/BI OR 20173-24-4/BI OR 2038-03-1/B
                 I OR 214778-10-6/BI OR 22476-61-5/BI OR 2516-47-4/BI OR
                 26386-88-9/BI OR 26663-77-4/BI OR 27489-62-9/BI OR 27578-60-5/B
                 I OR 308362-15-4/BI OR 308362-16-5/BI OR 308362-19-8/BI OR
                 3182-95-4/BI OR 324578-32-7/BI OR 324775-73-7/BI OR 340316-40-7
                 /BI OR 34840-23-8/BI OR 35303-76-5/BI OR 3544-24-9/BI OR
                 361457-34-3/BI OR 36692-49-6/BI OR 36743-66-5/BI OR 39130-93-3/
                 BI OR 41763-92-2/BI OR 425658-25-9/BI OR 4442-79-9/BI OR
                 4572-03-6/BI OR 462-08-8/BI OR 471294-42-5/BI OR 496846-39-0/BI
                  OR 500-22-1/BI OR 5081-36-7/BI OR 5471-55-6/BI OR 575449-52-4/
                 BI OR 5763-55-3/BI OR 58442-17-4/BI OR 590-86-3/BI OR 61587-91-
                 5/BI OR 62893-54-3/BI OR 630-19-3/BI OR 63435-16-5/BI OR
                 64-04-0/BI OR 64910-48-1/BI OR 64910-49-2/BI OR 6595-25-1/BI
                 OR 6638-79-5/BI OR 666181-01-7/BI OR 69570-97-4/BI OR 701293-60
                 -9/BI OR 701294-05-5/BI OR 701294-31-7/BI OR 704-13-2/BI OR
                 7154-73-6/BI OR 71605-72-6/BI OR 76-05-1/BI OR 78-39-7/BI OR
                 78-84-2/BI OR 82365-56-8/BI OR 828298-25-5/BI OR 85-41-6/BI OR
                 864273-75-6/BI OR 864273-76-7/BI OR 864273-77-8/BI OR 864273-78
                 -9/BI OR 864273-79-0/BI OR 864273-80-3/BI OR 864273-81-4/BI OR
                 864273-82-5/BI OR 864273-83-6/BI OR 864273-84-7/BI OR 864273-85
                 -8/BI OR 864273-86-9/BI OR 864273-87-0/BI OR 864273-88-1/BI OR
                 864273-89-2/BI OR 864273-90-5/BI OR 864273-91-6/BI OR

     FILE 'CAPLUS' ENTERED AT 14:05:55 ON 01 JUN 2009
L4         16600 SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  L3 AND PAC/RL
                 D E100-282

     FILE 'REGISTRY' ENTERED AT 14:08:02 ON 01 JUN 2009
                 D E100-E282

     FILE 'REGISTRY' ENTERED AT 14:11:16 ON 01 JUN 2009
L5               STRUCTURE UPLOADED
                 D
L6             4 SEA FILE=REGISTRY SSS SAM L5
L7            33 SEA FILE=REGISTRY SSS FUL L5
L8               STRUCTURE UPLOADED
                 D
L9             5 SEA FILE=REGISTRY SSS SAM L8
L10          137 SEA FILE=REGISTRY SSS FUL L8

     FILE 'MARPAT' ENTERED AT 14:14:14 ON 01 JUN 2009
L11            1 SEA FILE=MARPAT SSS SAM L8
L12            6 SEA FILE=MARPAT SSS FUL L8
                 D L12 IBIB AB 1-6

     FILE 'CAPLUS' ENTERED AT 14:17:46 ON 01 JUN 2009
L13            4 SEA FILE=CAPLUS SPE=ON  ABB=ON  PLU=ON  L7
                 D L13 IBIB GI ABD HITSTR
                 D L13 IBIB GI ABS HITSTR 1-4
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	27.06	506.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.10	-8.78

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:19:24 ON 01 JUN 2009